![Francis David Duke Scott](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Francis David Duke Scott
Director/Board Member at Clarington Corp.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Adrian Brouwers | M | - |
Clarington Corp.
![]() Clarington Corp. Investment ManagersFinance Part of iA Financial Corp., Inc., Clarington Corp. is a Canadian company that provides wealth management services. The company is based in Toronto, Canada. Clarington was acquired by Industrial Alliance Insurance & Financial Services, Inc. on January 10, 2006 for $169.68 million. The CEO of the company is Adrian Brouwers. | - |
Michael J. Hayes | M | 82 |
Clarington Corp.
![]() Clarington Corp. Investment ManagersFinance Part of iA Financial Corp., Inc., Clarington Corp. is a Canadian company that provides wealth management services. The company is based in Toronto, Canada. Clarington was acquired by Industrial Alliance Insurance & Financial Services, Inc. on January 10, 2006 for $169.68 million. The CEO of the company is Adrian Brouwers. | - |
Donald O. Wood | M | - |
Clarington Corp.
![]() Clarington Corp. Investment ManagersFinance Part of iA Financial Corp., Inc., Clarington Corp. is a Canadian company that provides wealth management services. The company is based in Toronto, Canada. Clarington was acquired by Industrial Alliance Insurance & Financial Services, Inc. on January 10, 2006 for $169.68 million. The CEO of the company is Adrian Brouwers. | - |
Terence B. Stone | M | - |
Clarington Corp.
![]() Clarington Corp. Investment ManagersFinance Part of iA Financial Corp., Inc., Clarington Corp. is a Canadian company that provides wealth management services. The company is based in Toronto, Canada. Clarington was acquired by Industrial Alliance Insurance & Financial Services, Inc. on January 10, 2006 for $169.68 million. The CEO of the company is Adrian Brouwers. | - |
Onofrio Sinopoli | M | - |
Clarington Corp.
![]() Clarington Corp. Investment ManagersFinance Part of iA Financial Corp., Inc., Clarington Corp. is a Canadian company that provides wealth management services. The company is based in Toronto, Canada. Clarington was acquired by Industrial Alliance Insurance & Financial Services, Inc. on January 10, 2006 for $169.68 million. The CEO of the company is Adrian Brouwers. | - |
Salvatore Tino | M | - |
Clarington Corp.
![]() Clarington Corp. Investment ManagersFinance Part of iA Financial Corp., Inc., Clarington Corp. is a Canadian company that provides wealth management services. The company is based in Toronto, Canada. Clarington was acquired by Industrial Alliance Insurance & Financial Services, Inc. on January 10, 2006 for $169.68 million. The CEO of the company is Adrian Brouwers. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Jeffrey Abrams | M | 68 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 12 years |
James DeMesa | M | 66 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 years |
Bill Adams | M | 62 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 9 years |
Ken Galbraith | M | 61 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | - |
AnnKatrin Petersen-Jappelli | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 4 years |
Geoffrey W. Henson | M | 76 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 7 years |
Bruce A. Schmidt | M | 68 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 years |
Gary Bridger | M | 61 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 20 years |
Eve Elizabeth Slater | M | 78 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | - |
W. Keith Schilit | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
Kamran Alam | M | 50 |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 3 years |
Pieter Dorsman | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 years |
Andrew J. Rae | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 years |
Paul Brennan | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 4 years |
K. David Campagnari | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 8 years |
Mark Levonyak | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 1 years |
Gary Calandra | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | - |
Richard Winston DeVries | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
Elisabeth Whiting | F | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 5 years |
Renato T. Skerlj | M | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 8 years |
Steven Gillis | M | 71 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 12 years |
A. Neil Howell | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
William D. Milligan | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 years |
Jacob J. Clement | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 years |
Alistair Duncan | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 6 years |
Doug Johnson | M | - |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 years |
Colin R. Mallet | M | 80 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 13 years |
Walter Moos | M | 69 |
MIGENIX, Inc.
![]() MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 4 years |
Diane Gardiner | F | - |
AnorMED, Inc.
![]() AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 35 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Francis David Duke Scott
- Personal Network